Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: <i>post hoc</i> analyses of three randomized double‐blind studies

Jessica Ailani(Georgetown University), Sheena K. Aurora(Impel Neuropharma (United States)), Q. Zhang(Eli Lilly (United States)), Kory Schuh(Eli Lilly (United States)), Eric Pearlman(University of California, San Francisco), Arnold Nagy(Carolina Headache Institute)
European Journal of Neurology
October 9, 2019
Cited by 26


Related Papers